⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL603100 | 0.88 | — | — | |
| SCHEMBL1206985 | 0.72 | — | — | |
| SCHEMBL4630955 | 0.71 | CHRNB2 (0.35) | — | |
| SCHEMBL771963 | 0.70 | — | — | |
| SCHEMBL18228341 | 0.68 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL6961571 | 0.68 | — | — | |
| SCHEMBL1208896 | 0.68 | — | — | |
| SCHEMBL272115 | 0.67 | — | — | |
| SCHEMBL24208157 | 0.67 | CA2 (0.48) | — | |
| SCHEMBL3891537 | 0.67 | CHRNB2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121397-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN INC (US) | 2021-04-29 | — | — | US | claimed |
| US-10881608-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2021-01-05 | — | — | US | claimed |
| EP-3426649-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Respivert Limited (GB) | 2019-01-16 | — | — | EP | claimed |
| WO-2017153748-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2017-09-14 | — | — | WO | claimed |
| EP-1742610-B1 | INTRAVITREAL IMPLANTS COMPRISING MICROSPHERES WHICH ENCAPSULATE A TYROSINE KINASE INHIBITOR AND A BIODEGRADABLE POLYMER | ALLERGAN INC (US) | 2013-06-12 | — | — | EP | claimed |
| EP-1902024-B1 | KINASE INHIBITORS | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | claimed |
| EP-1750665-B1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE INHIBITORS IMPLANTS | ALLERGAN INC (US) | 2012-07-11 | — | — | EP | claimed |
| US-8034957-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2011-10-11 | — | — | US | claimed |
| US-7915443-B2 | Sulfoximines as kinase inhibitors | ALLERGAN, INC. (US) | 2011-03-29 | — | — | US | claimed |
| US-7749530-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-07-06 | — | — | US | claimed |
| US-7015220-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-03-21 | — | — | US | claimed |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-02-02 | — | — | US | claimed |
| US-20040198802-A1 | Kinase inhibitors for the treatment of disease | ALLERGAN, INC. | 2004-10-07 | — | — | US | claimed |
| US-20040198720-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ANDREWS STEVEN W (US) | 2004-10-07 | — | — | US | claimed |
| US-6765012-B2 | FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | ALLERGAN, INC. | 2004-07-20 | — | — | US | claimed |
| EP-1430048-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| WO-2004050621-A2 | INDOL DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | ALLERGAN, INC (US) | 2004-06-17 | — | — | WO | claimed |
| US-20040102509-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | ALLERGAN, INC. | 2004-05-27 | — | — | US | claimed |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-10-23 | — | — | US | claimed |
| WO-2003027102-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | claimed |